Glover. The letter discusses trends in R&D for inflammasome inhibitors, specifically the company's Inflammasome ASC Inhibitor IC 100, which is being developed to treat chronic inflammatory diseases.

Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study.

ZyVersa CEO Stephen Glover said, “ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases, with ...

Fig. 1 | The NLRP3 inflammasome is an upstream activator of IL-1β and IL-18. NodThera is employing novel chemistry to create small molecules that inhibit the NLRP3 inflammasome that have now ...

Fox Foundation, has published promising data on its inflammasome ASC Inhibitor, IC 100, as a potential treatment for Parkinson's Disease (PD). The study demonstrates that IC 100 effectively blocks ...

Neushen Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, cardiovascular disorders, neurodegeneration and chronic obstructive ...

Yes-associated protein (YAP) is a core effector molecule of the Hippo signaling pathway, which regulates transcription and controls cell proliferation and growth. However, the role of YAP in ...